JP2018504419A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504419A5 JP2018504419A5 JP2017540316A JP2017540316A JP2018504419A5 JP 2018504419 A5 JP2018504419 A5 JP 2018504419A5 JP 2017540316 A JP2017540316 A JP 2017540316A JP 2017540316 A JP2017540316 A JP 2017540316A JP 2018504419 A5 JP2018504419 A5 JP 2018504419A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- motif
- sequence
- amino acids
- cst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 102000043131 MHC class II family Human genes 0.000 claims 5
- 108091054438 MHC class II family Proteins 0.000 claims 5
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- 108010076181 Proinsulin Proteins 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1418433.7A GB201418433D0 (en) | 2014-10-17 | 2014-10-17 | Novel immunogenic peptides |
| GB1418433.7 | 2014-10-17 | ||
| PCT/EP2015/074063 WO2016059236A1 (en) | 2014-10-17 | 2015-10-16 | Novel immunogenic peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016331A Division JP2020079271A (ja) | 2014-10-17 | 2020-02-03 | 新規な免疫原性ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504419A JP2018504419A (ja) | 2018-02-15 |
| JP2018504419A5 true JP2018504419A5 (enExample) | 2018-11-22 |
| JP6655626B2 JP6655626B2 (ja) | 2020-02-26 |
Family
ID=52013133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540316A Active JP6655626B2 (ja) | 2014-10-17 | 2015-10-16 | 新規な免疫原性ペプチド |
| JP2020016331A Pending JP2020079271A (ja) | 2014-10-17 | 2020-02-03 | 新規な免疫原性ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016331A Pending JP2020079271A (ja) | 2014-10-17 | 2020-02-03 | 新規な免疫原性ペプチド |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20180228912A1 (enExample) |
| EP (2) | EP3207053B1 (enExample) |
| JP (2) | JP6655626B2 (enExample) |
| KR (1) | KR102556485B1 (enExample) |
| CN (1) | CN107148427B (enExample) |
| AU (2) | AU2015332621B2 (enExample) |
| BR (1) | BR112017007773A2 (enExample) |
| CA (1) | CA2964426C (enExample) |
| DK (1) | DK3207053T3 (enExample) |
| ES (1) | ES2751605T3 (enExample) |
| GB (1) | GB201418433D0 (enExample) |
| MX (1) | MX374635B (enExample) |
| PL (1) | PL3207053T3 (enExample) |
| PT (1) | PT3207053T (enExample) |
| RU (1) | RU2709711C2 (enExample) |
| WO (1) | WO2016059236A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| EP2247306B1 (en) | 2008-02-14 | 2018-04-18 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
| EP2719396B1 (en) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
| ES2869155T3 (es) | 2010-11-25 | 2021-10-25 | Imnate Sarl | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201418433D0 (en) * | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| WO2019113342A1 (en) | 2017-12-07 | 2019-06-13 | Sanford Burnham Prebys Medical Discovery Institute | Compositions and methods for treating nervous system injuries |
| WO2017040976A1 (en) | 2015-09-02 | 2017-03-09 | Erkki Ruoslahti | Compounds and compositions for targeting brain injuries and methods of use thereof |
| EP3352782B1 (en) | 2015-09-25 | 2021-03-31 | ImCyse SA | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| KR20220132023A (ko) | 2016-04-19 | 2022-09-29 | 임시스 에스에이 | 신규 면역원성 CD1d 결합 펩티드 |
| SG11201908275XA (en) * | 2017-03-09 | 2019-10-30 | Imcyse Sa | Peptides and methods for the treatment of diabetes |
| US20210401976A1 (en) * | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
| CA3138713A1 (en) | 2019-05-16 | 2020-11-19 | Imcyse Sa | Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine |
| CN114746111A (zh) | 2019-11-27 | 2022-07-12 | 易姆赛斯股份公司 | 用于对糖尿病患者进行分层的方法 |
| CU20220066A7 (es) | 2020-05-06 | 2023-06-13 | Imcyse Sa | Péptidos inmunogénicos útiles en el tratamiento de esclerosis múltiple |
| AU2021266401A1 (en) | 2020-05-06 | 2022-12-15 | Imcyse Sa | Immunogenic peptides with new oxidoreductase motifs |
| JP2023525276A (ja) * | 2020-05-06 | 2023-06-15 | アンシス・エスア | 延長された酸化還元酵素モチーフを有する免疫原性ペプチド |
| EP4146190A2 (en) * | 2020-05-06 | 2023-03-15 | Imcyse SA | Combination treatment for fumarate-related diseases |
| EP3915575A1 (en) * | 2020-05-29 | 2021-12-01 | Imnate Sarl | Vaccine formulations |
| EP4321528A4 (en) * | 2021-04-09 | 2025-04-30 | Ajou University Industry-Academic Cooperation Foundation | PEPTIDE FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES |
| BR112023024116A2 (pt) | 2021-05-26 | 2024-02-06 | Imcyse Sa | Métodos de tratamento ou prevenção de doenças autoimunes |
| PH12023553212A1 (en) | 2021-06-01 | 2024-02-19 | Imcyse Sa | Improved methods of treatment using immunogenic peptides |
| WO2022256637A2 (en) * | 2021-06-03 | 2022-12-08 | David Weiner | Synthetic dna vaccine immunogenic improvements |
| AR126654A1 (es) | 2021-06-29 | 2023-11-01 | Imcyse Sa | Péptidos y métodos para el tratamiento de neuromielitis óptica |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4886782A (en) | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
| US5433948A (en) | 1990-02-13 | 1995-07-18 | Thomas; Wayne R. | Cloning and sequencing of allergens of dermatophagoides (house dust mite) |
| AU650911B2 (en) | 1990-09-27 | 1994-07-07 | Syntello Vaccine Development Kb | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
| US7252829B1 (en) | 1998-06-17 | 2007-08-07 | Idm Pharma, Inc. | HLA binding peptides and their uses |
| US5589582A (en) | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
| US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| JP3926839B2 (ja) | 1993-09-14 | 2007-06-06 | エピミューン，インコーポレイティド | 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変 |
| US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
| AU1124499A (en) | 1997-10-28 | 1999-05-17 | Maxygen, Inc. | Human papillomavirus vectors |
| NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| US20030152581A1 (en) | 1998-07-30 | 2003-08-14 | Jean-Marie Saint-Remy | Compound and method for the prevention and/or the treatment of allergy |
| AR020102A1 (es) | 1998-07-30 | 2002-04-10 | Ucb Sa | Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento |
| HK1044040A1 (zh) | 1998-11-16 | 2002-10-04 | 德克萨斯州立大学董事会 | Hiv-特异的t-细胞诱导 |
| US7780882B2 (en) | 1999-02-22 | 2010-08-24 | Georgetown University | Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent |
| EP2311951A1 (en) | 2000-01-28 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| GB0006437D0 (en) | 2000-03-17 | 2000-05-10 | Leuven Res & Dev Vzw | Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens |
| EP1294905A1 (en) | 2000-06-26 | 2003-03-26 | SmithKline Beecham Biologics SA | Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| EP1409650B1 (en) | 2001-05-30 | 2006-04-12 | Fondazione Telethon | Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof |
| CA2458392A1 (en) | 2001-10-03 | 2003-04-17 | Unilever Plc | Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| US20100183652A1 (en) | 2002-02-21 | 2010-07-22 | Mark Page | STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS |
| AU2003215395A1 (en) | 2002-02-21 | 2003-09-09 | Apovia, Inc. | STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS |
| DK2261249T3 (en) | 2002-09-12 | 2015-02-16 | Oncotherapy Science Inc | KDR peptides and vaccines comprising the same |
| WO2005012502A2 (en) | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| US7651855B2 (en) | 2003-04-17 | 2010-01-26 | The Trustees Of The University Of Pennsylvania | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses |
| EP1670509A4 (en) | 2003-09-03 | 2007-10-31 | Dendritherapeutics Inc | MULTIPLEX VACCINES |
| GB0324265D0 (en) | 2003-10-16 | 2003-11-19 | Medical Res Council | Peptide |
| US20070184023A1 (en) | 2003-10-30 | 2007-08-09 | Pharmexa A/S | Method for down-regulation of vegf |
| KR20070056042A (ko) | 2004-06-17 | 2007-05-31 | 맨카인드 코포레이션 | 에피토프 유사체 |
| US8252893B2 (en) | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
| WO2007027954A2 (en) | 2005-08-30 | 2007-03-08 | Children's Hospital & Research Center At Oakland | Methods for identifying an epitope of a polypeptide, chlamydial antigenic polypeptides identified thereby, and methods of use thereof |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
| WO2007135684A2 (en) | 2006-05-22 | 2007-11-29 | Hadasit Medical Research Services & Development Limited | Method of treatment of anti-cd4 autoimmunity |
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| WO2008145400A2 (en) | 2007-05-31 | 2008-12-04 | Medigene Ag | Mutated structural protein of a parvovirus |
| US8546137B2 (en) | 2007-09-27 | 2013-10-01 | The Board Of Trustees Of The University Of Arkansas | Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor |
| EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| EP2247306B1 (en) | 2008-02-14 | 2018-04-18 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
| US20100330088A1 (en) | 2008-02-14 | 2010-12-30 | Jean-Marie Saint-Remy | Strategies to prevent and/or treat immunie responses to soluble allofactors |
| CA2715517C (en) | 2008-02-14 | 2018-07-24 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in preventing or treating allograft rejection |
| EP2719396B1 (en) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
| CA2715484C (en) | 2008-02-14 | 2017-04-11 | Life Sciences Research Partners Vzw | Suppression of immune responses to viral vectors |
| AU2009214041A1 (en) | 2008-02-14 | 2009-08-20 | Katholieke Universiteit Leuven | CD4+ T-cells with cytolytic properties |
| EP2254592B1 (en) | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| KR101022649B1 (ko) | 2008-08-07 | 2011-03-22 | 삼성모바일디스플레이주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치 |
| RU2016137258A (ru) | 2009-04-01 | 2018-12-13 | Юниверсити Оф Майами | Композиции вакцин и способы их применения |
| WO2011120994A1 (en) | 2010-03-29 | 2011-10-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof |
| ES2869155T3 (es) * | 2010-11-25 | 2021-10-25 | Imnate Sarl | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica |
| GB201201511D0 (en) * | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| NZ722352A (en) | 2012-02-15 | 2022-05-27 | Ecole Polytechnique Fed Lausanne Epfl | Erythrocyte-binding therapeutics |
| EP2844741A1 (en) * | 2012-04-30 | 2015-03-11 | ImCyse SA | Methods for induction of antigen-specific regulatory t cells |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| GB201319160D0 (en) | 2013-10-30 | 2013-12-11 | Imcyse Sa | Methods for induction of antigen-specific regulatory t cells |
| JP2017500285A (ja) | 2013-11-04 | 2017-01-05 | ユーティーアイ リミテッド パートナーシップ | 持続的免疫療法のための方法および組成物 |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| EP3352782B1 (en) | 2015-09-25 | 2021-03-31 | ImCyse SA | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| KR20220132023A (ko) | 2016-04-19 | 2022-09-29 | 임시스 에스에이 | 신규 면역원성 CD1d 결합 펩티드 |
| SG11201908275XA (en) | 2017-03-09 | 2019-10-30 | Imcyse Sa | Peptides and methods for the treatment of diabetes |
| US20210401976A1 (en) | 2018-11-12 | 2021-12-30 | Imcyse Sa | Immunogenic peptides with improved oxidoreductase motifs |
| CA3138713A1 (en) | 2019-05-16 | 2020-11-19 | Imcyse Sa | Immunogenic peptides with an oxidoreductase motif comprising a modified cysteine |
-
2014
- 2014-10-17 GB GBGB1418433.7A patent/GB201418433D0/en not_active Ceased
-
2015
- 2015-10-16 BR BR112017007773-6A patent/BR112017007773A2/pt active Search and Examination
- 2015-10-16 WO PCT/EP2015/074063 patent/WO2016059236A1/en not_active Ceased
- 2015-10-16 EP EP15787917.2A patent/EP3207053B1/en active Active
- 2015-10-16 CN CN201580056434.6A patent/CN107148427B/zh active Active
- 2015-10-16 AU AU2015332621A patent/AU2015332621B2/en active Active
- 2015-10-16 PL PL15787917T patent/PL3207053T3/pl unknown
- 2015-10-16 ES ES15787917T patent/ES2751605T3/es active Active
- 2015-10-16 RU RU2017111657A patent/RU2709711C2/ru active
- 2015-10-16 KR KR1020177012944A patent/KR102556485B1/ko active Active
- 2015-10-16 CA CA2964426A patent/CA2964426C/en active Active
- 2015-10-16 PT PT157879172T patent/PT3207053T/pt unknown
- 2015-10-16 DK DK15787917T patent/DK3207053T3/da active
- 2015-10-16 JP JP2017540316A patent/JP6655626B2/ja active Active
- 2015-10-16 US US15/516,045 patent/US20180228912A1/en not_active Abandoned
- 2015-10-16 EP EP19192582.5A patent/EP3636666A1/en not_active Withdrawn
- 2015-10-16 MX MX2017004780A patent/MX374635B/es active IP Right Grant
-
2019
- 2019-10-17 AU AU2019250206A patent/AU2019250206A1/en not_active Abandoned
-
2020
- 2020-02-03 JP JP2020016331A patent/JP2020079271A/ja active Pending
- 2020-06-04 US US16/892,588 patent/US12023384B2/en active Active
-
2024
- 2024-05-24 US US18/674,092 patent/US20240342297A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017111657A (ru) | Новые иммуногенные пептиды | |
| RU2018136760A (ru) | НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ | |
| AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| CL2019003427A1 (es) | Nuevos péptidos (seq id n°180), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| FI3430027T3 (fi) | Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa | |
| PE20240645A1 (es) | Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores | |
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| RU2014135406A (ru) | Модифицированные эпитопы для усиления ответов cd4+ т-клеток | |
| RU2015122368A (ru) | Слитые белки для применения в качестве иммуногенных усиливающих агентов для индуцирования антигенспецифического т-клеточного ответа | |
| MX2024006356A (es) | Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia | |
| EA201790976A1 (ru) | Терапевтические вакцины против hpv16 | |
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| JP2018528237A5 (enExample) | ||
| EP3939606A3 (en) | Improved methods and compounds for eliminating immune responses to therapeutic agents | |
| MX377692B (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| EP3792628A3 (en) | Methods for predicting the usefulness of neoantigens for immunotherapy | |
| MX387764B (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| CR20200432A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 2. 2018-74) | |
| MY177371A (en) | Peptides | |
| CL2019003328A1 (es) | Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer. (divisional solicitud 201703244) | |
| NZ596501A (en) | Casb7439 constructs | |
| RU2010126154A (ru) | Эпитопные пептиды stat3 | |
| ZA202100761B (en) | Improvements in immunogenic conjugates | |
| PH12023553212A1 (en) | Improved methods of treatment using immunogenic peptides |